The Cell line Development Market was valued at USD 4.5 Bn in year 2021 and is expected to grow at a strong CAGR of around 10% during the forecast period (2022-2030)
The cell line development market is witnessing significant growth driven by rapid advancements in gene editing technologies, a well-established biotechnology sector, and supportive government policies coupled with robust funding initiatives. A notable example is Thermo Fisher Scientific’s announcement on March 25, 2021, confirming the U.S. FDA listing of their Applied BioSystems Quant Studio 5 Dx Real-Time PCR System. This innovative system aids assay developers and clinical laboratories in meeting regulatory testing requirements while streamlining molecular diagnostics workflows.
Additionally, the increasing use of cell lines in regenerative medicine and the rising demand for biopharmaceuticals are further propelling market growth in North America. The region is projected to grow at a strong compound annual growth rate (CAGR) of 10.0% between 2022 and 2028, with the U.S. and Canada leading due to surging biopharmaceutical demand, an aging population, and a rising prevalence of chronic diseases.
The biopharmaceutical industry in North America is also experiencing heightened innovation and competition, partly due to the expiration of biologic patents. This has spurred the development of newer and improved cell lines for biologics production. For instance, in April 2022, Kite, a Gilead company, received FDA approval for Yescarta (axicabtagene ciloleucel), a CAR T-cell therapy for adult patients with refractory or relapsed large B-cell lymphoma, marking a significant milestone in personalized cancer treatments.
Access sample report (including graphs, charts, and figures): https://univdatos.com/reports/cell-line-development-market?popup=report-enquiry
Market Segmentation by Cell Line
The market is segmented into recombinant, hybridomas, continuous cell lines, and primary cell lines. Among these, the primary cell line segment is anticipated to exhibit significant growth over the forecast period. This growth is driven by the increasing demand for high-quality cell lines in drug development and research. Moreover, primary cell lines are increasingly adopted for therapeutic protein production, vaccine manufacturing, and gene editing applications, such as CRISPR/Cas9 technologies.
For example, Zon Discovery Group launched the Edit-R CRISPRa Portfolio in 2020, a collection of plasmids that leverage CRISPR activation technology to upregulate specific gene expressions in mammalian cells, showcasing the integration of gene-editing tools in cell line development.
Market Segmentation by Source
Based on the source, the market divides into mammalian and non-mammalian cell lines. Mammalian cell lines accounted for the majority share in 2021 due to their critical role in producing monoclonal antibodies and high-quality cell lines for research and drug development. The rising demand for biopharmaceuticals, many of which rely on mammalian cell systems for production, continues to drive growth in this segment.
Click here to view the Report Description & TOC: https://univdatos.com/reports/cell-line-development-market
Market Segmentation by Product and Application
The product segment includes reagents and media, equipment, finished cells, and other related components essential for cell line development. Meanwhile, key applications include recombinant protein expression, hybridoma technology, vaccine production, drug discovery, and other emerging uses.
Regional Insights
North America leads the global market, with significant contributions from the U.S. and Canada. Europe follows, with Germany, the U.K., France, Italy, and Spain as prominent markets. The Asia-Pacific (APAC) region, including China, Japan, and India, is rapidly growing, fueled by expanding biotech industries and increased healthcare investments. The rest of the world also presents emerging opportunities driven by growing awareness and adoption of advanced cell line technologies.
Key Players in the Market
Several major companies dominate the cell line development market, including:
- GE Healthcare
- Lonza
- Sartorius AG
- WuXi AppTec
- Merck KGaA
- Selexis SA
- Thermo Fisher Scientific Inc.
- Corning Incorporated
- Danaher
- ATCC
These companies continuously innovate to develop new technologies, products, and services that support the expanding demand for cell line development in research, biopharmaceutical production, and therapeutic applications.
Contact Us:
UnivDatos
Email: contact@univdatos.com
Contact no: +1 978 7330253
Website: www.univdatos.com
